PAAB: Update on Digitization of Advertising / Promotional Systems (APS)

PAAB: Update on Digitization of Advertising / Promotional Systems (APS)

Published on 18 Mar 2020

Author:  Preetha Prabhu

In the light of evolving COVID-19, some manufacturers are modifying how their drug representatives interact with healthcare professionals. PAAB has taken measures to help healthcare product manufacturers comply with regulations during this evolving operational context.

Creation:

APS that have undergone pre-clearance for use as print materials can be converted to electronic document types (e.g. PDF) without additional PAAB pre-clearance or review provided all of the following conditions are met:

  • The entire PAAB approved print document is converted with no change in copy, flow or layout. For example, any size changes are directly proportional throughout the APS.
  • No new functionality is added. For example, the document is a flat PDF as opposed to a dynamic PDF with new interactive functionality (e.g. menus, pop-ups, accordions, hover-over tool tips, and so on).
  • The print piece is within its PAAB approval period.

Please note that APS digitized in this manner can be distributed to healthcare professionals without informing the PAAB through an FYI notification. These APS should bear the PAAB logo.

Dissemination:

Emails used to distribute digitized APS in an unsolicited fashion DO NOT fall under the person-to-person correspondence exemptions in the PAAB code or advertising regulation exemptions in the Health Canada Policy Document “The Distinction Between Advertising and Other Activities”. These emails with attached APS are subject to PAAB review.

To facilitate the review, PAAB recommend submitting an email template. It can include free text portions for transactional elements (e.g. greeting, date and time of phone meeting, sign-off). This enables the template to be multi-purpose and reusable for a variety of products/APSs. It is important that the individuals sending these emails be trained to not include information about the product, disease, or related company services in those free text portions. These individuals should also be trained to not send product branded and unbranded tools in the same email. The submission of the email template should include detailed information regarding the naming convention for email attachments.

PAAB will work with industries to expedite reviews related to digitization efforts.

 Reference:

Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context (Dated Mar. 13, 2020) https://www.paab.ca/resources/clarification-regarding-digitization-of-aps/

Related Articles

Non-medical masks or face coverings: Regulatory considerations in the context of COVID-19

Non-medical masks or face coverings: Regulatory considerations in the context of COVID-19

On July 24, 2020, Health Canada published a notice to industry that explains circumstances under which non-medical masks or face coverings would be subject to the regulatory...

Step 2b draft Q3C(R8): Impurities: Guideline for Residual solvents – Released for public consultation

Step 2b draft Q3C(R8): Impurities: Guideline for Residual solvents – Released for public consultation

The ICH Q3C core guideline was finalized under Step 4 in July 1997, providing recommendations on the use of less toxic solvents in the manufacture of drug substances and...